NIH Reporter #1R37CA315256-01

NCI Grant for Nanoparticle-Based Cancer Immunotherapy Research

This opportunity is a research grant offered by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on advancing cancer immunotherapy through nanoparticle technology. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Project Scope: - Research on 'Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles' - Aims to develop a prime-pull vaccination platform for metastatic melanoma and other aggressive cancers - Includes preclinical studies, biodistribution analysis, and immune response characterization - Products/Services Requested: - No specific products, part numbers, or purchase quantities are listed - No OEMs or vendors are named - Unique/Notable Requirements: - Focus on innovative cancer immunotherapy using advanced nanoparticle adjuvants - Opportunity is for research funding, not product procurement

Description

This NIH grant opportunity focuses on developing a prime-pull vaccination platform using super-adjuvant nanoparticles to improve treatment outcomes in metastatic melanoma and other aggressive cancers. The project involves conducting preclinical studies, analyzing biodistribution, and characterizing immune responses. It is funded by the National Cancer Institute (NCI), part of the NIH. No specific line items or bid schedule are provided.

View original listing